Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome.

Kopytek, M.; Natorska, J.; Undas, A.

Objectives: Antibodies to phosphatidylserine/prothrombin complex (aPS/PT) detectable in sera of some patients with antiphospholipid syndrome (APS) have been shown to correlate with thrombosis. However, associations of aPS/PT antibodies with APS related disorders remain unclear. Aim: To evaluate whether there are any associations between aPS/PT antibodies and Raynaud phenomenon, migraine and/or valvular lesions in primary thrombotic APS (PAPS). Methods: We enrolled 67 consecutive patients (56 women) with thrombotic PAPS (VTE in 80.6%), aged 46.2 ± 13.5 years. The exclusion criteria were: acute coronary syndromes or stroke within preceding 6 months, cancer, severe comorbidities and pregnancy. The IgG and IgM aPS/PT antibodies were determined by ELISA with the cut-off of 30 units. We recorded Raynaud phenomenon, migraine and valvular lesions. Results: Positive IgM or/and IgG aPS/PT antibodies were observed in 29 patients (43.3%), with a higher prevalence of IgM antibodies (n = 27, 40.3%) compared with IgG isotype (n = 12, 17.9%, p = 0.014). aPS/PT antibodies were observed most commonly in patients with triple aPL (n = 12, 85.7%) compared with those with double (n = 5, 35.7%) or single aPL antibodies (n = 12, 30.8%, p = 0.03), with no association with demographics, the ANA titre, the type of thrombotic events or medications. Raynaud phenomenon, migraine and valvular lesions were observed in 15% (n = 10), 30% (n = 20) and 18% (n = 12) of the patients, respectively. Raynaud phenomenon and migraine, but not valvular lesions, were markedly more frequent in PAPS patients presenting with positive aPS/PT antibodies (n = 10, 34.5% vs. n = 0, 0%; p = 0.0001). Conclusions: In PAPS patients aPS/PT antibodies are related to the occurrence of both Raynaud phenomenon and migraine.

PHOSPHOLIPID antibodies; PROTHROMBIN; RAYNAUD'S disease; MIGRAINE; ANTIPHOSPHOLIPID syndrome; THROMBOSIS; THERAPEUTICS

Lupus, 2018, Vol 27, Issue 5, p812

0961-2033

Academic Journal

10.1177/0961203317751644